Greetings from Barcelona, Spain! From March 11–14, 2026, the world’s leading type 1 diabetes (T1D) researchers, healthcare professionals, and industry partners gathered to share groundbreaking advances in T1D science—and Breakthrough T1D–supported work (and staff) were front and center.

Below is everything you need to know from the first two days of this remarkable conference, including key takeaways from panels and sessions chaired by Breakthrough T1D staff and supported researchers. Featured participants included Breakthrough T1D CEO Aaron Kowalski, Ph.D.; Chief Scientific Officer Sanjoy Dutta, Ph.D.; Thomas Danne, M.D., Ph.D., Chief Medical Officer; Vice President of Medical Affairs Anastasia Albanese O’Neill, Ph.D., APRN, CDCES; and many more.

Screening

T1D Screening and Early Detection is a key mission priority for Breakthrough T1D—and multiple presentations illustrated how important it is, and why we need to screen more people to achieve our vision of a world without T1D.

The landscape of T1D screening today is incredibly exciting—and has come a very, very long way in recent years. Across the globe, the number of people being screened, which includes kids and adults, is growing significantly. In addition to the U.S., screening numbers are on the rise across Europe, Australia, Qater, Israel, and now in Central America.

So—what are some big takeaways on screening?

Global screening programs

EDENT1FI, a European screening initiative supported by Breakthrough T1D, presented data from around the world on screening for early detection. One of the presenters was Breakthrough T1D VP of Medical Affairs, Anastasia Albanese-O’Neill, Ph.D., APRN, CDCES, who shared our screening strategy and underscored the importance of international consensus recommendations for screening and monitoring that can be used in clinical care.  This session outlined the global scope of screening that Breakthrough T1D is supporting.

Breakthrough T1D is funding a truly global network of screening programs. From ELSA in the United Kingdom to ASK and TrialNet in the U.S. to FR1DA in Germany, all these centers are working together to build the case for general population screening. They’re doing this by improving outcomes for people with detected autoantibodies, providing follow-up monitoring, enrolling eligible individuals in clinical trials (including Breakthrough T1D-funded INNODIA), offering FDA-approved therapies like teplizumab (Tzield), and learning the best ways to educate and inform people of the benefits and logistics of screening and follow-up monitoring.

Education and communication are key. One incredible learning from Italy and the United Kingdom is how people learn about screening. For the majority of individuals, it’s through school and through social media. It’s up to all of us to help spread the word. Learn more about our screening programs here.

Another key takeaway from the ELSA study: no one who learns that they have T1D autoantibodies regrets having that knowledge. However, there are gaps around how we can help people with that information and how we can better support families who have detected T1D early.

Free, voluntary general population screening for T1D and Celiac Disease is now law in Italy. Francesca Ulivi from the Italian Diabetes Foundation shared what Italy is learning about how they are increasing the number of people screening—and to add to an earlier note, education is key.

Clinical adoption of T1D screening

In 2024, Breakthrough T1D led the way with the publication of Consensus Guidance for Monitoring Persons with Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. This report contains guidelines for what to do when T1D autoantibodies are detected—but it does not touch on the bigger question: who to screen?

To make the case for general population screening, Breakthrough T1D convened a group of international experts to establish guidance for the clinical adoption of screening for early detection. This paper is expected to be published later this year and will be a clinical roadmap for general population screening—so more people can realize the benefits.

Breakthrough T1D Chief Scientific Officer, Sanjoy Dutta, Ph.D., also spoke to our organization’s vision for expanding general population screening.

Breakthrough T1D is funding a series of pilot screening programs across the country. These centers aim to develop and test diabetes center workflows for screening and monitoring for T1D. We are learning a lot from these, as presented by Carla Demeterco-Berggren, M.D., who runs a Breakthrough T1D-funded screening pilot in San Diego. Some key takeaways:


Disease-modifying therapies

Disease-modifying therapies (DMTs) have the potential to change the course of T1D by slowing, halting, or reserving its progression. Teplizumab (called Tzield in the U.S.) was the first DMT approved by the FDA in November 2022 for individuals with early-stage T1D, delaying the onset of clinical, symptomatic T1D and the need for insulin therapy by a median of two years. Since its approval, and thanks to increased education and awareness around screening, hundreds of people have had the opportunity to benefit from teplizumab.

Breakthrough T1D and Tzield

Learn more about the first disease-modifying therapy for T1D and how Breakthrough T1D helped guide it through every stage of therapy development.

The changing landscape of available T1D therapies requires healthcare professionals (HCPs) to consider how to best work within existing care structures to support their patients who are using therapies like teplizumab. In an informative session led by Breakthrough T1D-funded researchers Prof. Colin Dayan, BSc, MBChB, Ph.D., FRCP from Cardiff University, Michael Haller, M.D. from the University of Florida, and Prof. Olga Kordonouri from Children’s Hospital Auf der Bult in Hannover, Germany, these superstar endocrinologists walk us through practical considerations for use of teplizumab in clinics and real-world experiences from the perspective of both teplizumab recipients and caregivers.


Cell therapies

While the current standard of care for T1D has taken immense strides in the recent past, one thing is abundantly clear: people with T1D are not doing well enough. Per data presented by Breakthrough T1D-funded researchers Jason Gaglia, M.D., Trevor Reichman, M.D., Jennifer Sherr, M.D., and Jay Skyler, M.D. at Vertex Pharmaceuticals’ Industry Session, globally, about 25% of people with T1D are hitting their ideal HbA1c target of under 7%. Automated insulin delivery (AID) systems—which have been transformative for T1D care—are improving outcomes, but the majority of people are not achieving their ideal goals. This means that most people with T1D are more at risk for the most common complications of the condition, including heart disease, kidney disease, and diabetic eye disease.

Among the individuals who are achieving ideal HbA1c goals, an acute complication begins to emerge: severe hypoglycemic events.

This paints a pretty clear picture: we need better therapies to help people do better, and cell therapies have the potential to fill the gaps between how people are currently doing and where they need to be to prevent long-term and acute complications.

Currently, deceased-donor islet transplants are an option, but they are not an option for the majority of people with T1D due to a scarcity of deceased-donor islet cells (it can take 4 donor pancreases to get enough cells for one person) and the drawbacks of chronic immunosuppression.

The future Vertex and the field at large is driving toward is one where manufactured islets are mass produced at scale, which solves the scarcity problem, and are used with novel techniques to keep them safe from the immune system—including gene-edited cells and alternatives to modern immunosuppression (like Eledon’s tegoprubart).

One other note: someone in the audience inquired as to why more people in the U.S. do not receive islet transplants. The panelists were in agreement that it is due to the current regulatory environment for deceased-donor islet cells, which classifies them as biologics, not organs. This reinforces Breakthrough T1D’s efforts to urge the Department of Health and Human Services to reclassify deceased-donor islet cells as organs—which it has the legal authority to do now.


Improving Lives

All the major T1D tech companies were present and accounted for at ATTD. Omnipod, Abbott, Tandem, Minimed, Dexcom, and more highlighted their current devices and how they can improve diabetes management.

We’re not going to cover the specifics of these devices, but one theme was consistent throughout the presentations: people utilizing AID systems and continuous glucose monitors (CGM) have better outcomes.

But there were some exciting developments around adjunctive therapies, the use of artificial intelligence, and a new approach: gene therapy.

The use of Artificial intelligence (AI) is a hot topic at ATTD. This topic was presented by longtime Breakthrough T1D collaborator Boris Kovatchev, Ph.D., in the opening lecture and Giacomo Cappon, M.D., Marc Breton, Ph.D., and others in a plenary session chaired by Breakthrough T1D CEO Aaron Kowalski, Ph.D.

One of the more interesting areas discussed was the use of digital twins—virtual models of a person with T1D. These models allow researchers and clinicians to test potential changes in diabetes management in a simulated environment before talking through and implementing those adjustments in real life. The potential is big, but there are still risks. AI-generated “hallucinations,” e.g. 2 + 2 = 7, can occur, and any therapeutic recommendations need human review. Even so, the promise of these tools for T1D is significant.

Dr. Kovatchev and Dr. Breton also highlighted how AI is already being used in clinical trials. Their talks focused on AID As a Network (AIDANET), an AI-based AID system. This fully closed-loop setup—using a Dexcom G6, a Tandem t:slim insulin pump, and a smartphone—first learns from insulin pump and CGM data. Once it understands a person’s patterns, it takes over and fully automates insulin delivery. No mealtime announcements required.

Dr. Breton shared data from a Breakthrough T1D–funded study using AIDANET, and the results were striking. People who already had lower HbA1c levels saw modest improvements, while those starting with higher HbA1cs experienced significant gains. In this fully closed-loop, no-bolus approach, AIDANET was better than standard use across nearly every outcome for the 34 people in the clinical trial—and overall, it delivered superior glycemic control.

How does it achieve this? Essentially, AIDANET performs about as well as usual care during the day and then outperforms it at night.

Breakthrough T1D continues to fund this work, including the AIDANET clinical trial in adolescents and young adults that Dr. Breton presented. The takeaway so far: AIDANET delivers equivalent control for people who are already well managed—and even better outcomes for those with higher HbA1c levels.

And here’s something to look out for: there is an ongoing clinical trial testing AIDANET at home in over 50 people with T1D. The data should come out soon—and should be another proof point in support of the use of AI in T1D.

Gene therapy in T1D

Longtime Breakthrough T1D collaborator Jeremy Pettus, M.D., was in attendance to share information from Kriya Therapeutics, a T1D Fund portfolio company. Kriya is pursuing a gene therapy for T1D, and it’s an exciting new approach to achieving glycemic control.

Gene therapies explained

Gene therapies are still fairly new—there are 7 approved today, and they primarily are used for rare diseases. They work by using a safe, non-pathogenic virus to deliver genetic information into the nucleus of a cell. This process does not alter the individual’s chromosomes or genetic makeup but can correct genetic abnormalities or change the behavior of cells to treat disease.

Applications in T1D

Kriya’s approach is to modify muscle cells to secrete insulin. This is very different from, for example, beta cell therapies, which place insulin producing beta cells into people with T1D. In Kriya’s therapy, there are no new beta cells or transplanted cells that require immunosuppression—it’s just enabling muscle cells to make insulin.

The administration of this therapy is fairly straightforward. For 2-3 months in advance of the procedure, the recipient takes immunomodulatory drugs.  Then, they undergo a procedure where they receive intramuscular injections in both thigh muscles. Then, the person goes home. After 2-3 months, the cells are fully up to speed and making insulin, which has the potential to help control blood sugar levels and reduce insulin therapy requirements.

Clinical trials

In large animal models, the data is very encouraging—after receiving the therapy, blood glucose levels were normalized on the order of years. Based on this data, clinical trials are expected to begin in people this year.

This phase 1 clinical trial, called the Progress Study, will assess dosage and safety, and the phase 2 trial will expand to assess broader safety and efficacy.

This is a new and innovative approach supported by the T1D Fund. If you’re interested in participating in the clinical trial, stay tuned to our clinical trials page, which is regularly updated with opportunities like this.


Medical Affairs

Breakthrough T1D Chief Medical Office Thomas Danne, M.D., Ph.D. ,outlined the goals of our Medical Affairs team—which is to improve the world’s ability to accelerate implementation of current and future breakthroughs so that, ultimately, people with T1D can have better quality of life.

The current state of endocrinology globally is a growing concern.  For example, we don’t have enough endocrinologists and diabetes educators to take on of the growing and aging population of people with T1D. Clinical adoption for teplizumab, the first approved DMT for T1D, has been slow. We must build the infrastructure today to ensure that in the future, there isn’t a gap between the breakthroughs in the lab becoming breakthroughs for people with T1D.

Dr. Danne outlined the vision for a training program that will entice a new generation of endocrinologists as the field evolves and new methods of treating T1D are available. Breakthrough T1D and ATTD are supporting a certificate program for an interventional diabetologist, which includes training in immunology, using immune therapies to treat individuals in stage 1 and stage 2, education on cell therapies for those in stage 3 and stage 4, and the other advancements in the pipeline.  He also spoke about other work the Medical Affairs team is involved in including the Centers of Reference, an international collaboration creating a roadmap for implementing manufactured cell therapies into clinics once they become available.


More to come!

We have even more exciting updates to share with you. Keep an eye out for our recap of days 3 & 4 of ATTD, coming next week!

This article was written by Brian Herrick and Sandy Vogt, Ph.D.

Where it all began

I was diagnosed with type 1 diabetes (T1D) in 1979 in suburban Philadelphia. I had just finished kindergarten, learned to ride a bike, and spent summer days pedaling the block. I was thirsty all the time. I was a new little cyclist and it was summer, of course I was thirsty! One day I drank an entire quart of iced tea, within mere minutes, at a neighbor’s house. That was the red flag. My pediatrician sent us to the local hospital, and multiple nurses and a doctor held me down as they repeatedly struggled to find a vein for a blood draw. My Dad took me for pancakes afterwards—definitely not ideal without insulin. Later, there was a phone call and my Dad left the house. I saw him sitting outside with his head in his hands. It was the first time I saw him cry.  My Mom pulled me away from the window.

I spent the next week and a half in a children’s ward of a Philadelphia hospital. My parents were trained to care for me, and I practiced giving insulin shots on an orange while arts and crafts kept me busy. I spoke to my parents every night on a pay phone, whispering, while crying that I wanted to come home. My parents would say the other children in the ward needed me to be brave. This was long before continuous glucose monitors (CGMs) or even portable blood glucose meters. My parents learned to check my glucose by testing my urine with chemicals in test tubes, a non-exact way to measure glucose range. When I came home, neighbors were anxious because many believed diabetes was contagious.

A designer’s perspective on T1D clinical trials

Clinical trials and research have been central to my life. Clinical trials are essential to proving a concept, where ideas are tested rigorously and then refined.

My training as an industrial designer has always been about the intersection of people and systems. Whether designing a lighting fixture, a user interface, or an educational program, I think first about human needs, usability, and empathy.

That design lens informs how I view research. A study protocol is not just a list of procedures. It is a system that has users, interfaces, and outcomes. Participants are the users. Devices and consent forms are the interfaces. The data is the outcome. When design thinking is applied to research, studies become more accessible, clearer, and better aligned with the realities of daily life.

A defining experience

For those of us living with type 1 diabetes, research is not just academic—it is the path to a better quality of life. I have participated in nine clinical trials and numerous studies. I tested early automated insulin delivery (AID) systems over many years, assessing software and hardware which led to commercially available AID systems. I tested an implantable continuous glucose monitor, and I took part in studies that examined complications and diabetes biomarkers. Each trial taught me about technology, the human body (specifically mine), and how research truly impacts lives.

The experience that defined my clinical trial pathway was in my mid-20’s. I developed retinopathy. Due to a great macular specialist, I received aggressive laser treatments for years. It was scary, especially as a young professional starting a career in product development and visual design. The treatments that preserved my vision were possible because others had volunteered for research for years, even decades, before me. That reality gave me enormous gratitude, and it also gave me a sense of responsibility. Participating in research is how I have been able to embrace a life philosophy of “Do good, feel good” and ultimately pay it forward. Clinical trials and research studies are how we learn and design better solutions for everyone who follows.

Joining the Participant Advisory Council

My designer’s perspective led me to join the Breakthrough T1D Participant Advisory Council (PAC). I had been involved with Breakthrough T1D for many years as a Clinical Trial Education Volunteer, an advocate, and former board member. The PAC offered a new opportunity to bring lived experience directly into the research process.

On the council, we review trial designs, advise on participant burden, critique consent language, and recommend practical changes in the hope of lowering barriers to participation. My concern initially was that I’d be a token voice, but we are not. We are advisors who help researchers see the experience through the eyes of the people who will take part in the studies—people who may ultimately benefit from the data gained.

One of the most meaningful ways I contributed as a PAC member was in June 2025, when I spoke on a panel about disease-modifying therapies (DMTs) at the American Diabetes Association Scientific Sessions in Chicago. The panel focused on disease-modifying therapies designed to preserve C-peptide (a biomarker for insulin production) and slow or stop the progression of T1D. I represented the lived experience, and I brought the perspective of a long-term clinical trial participant and an educator who helps others understand and navigate research opportunities.

Using my voice to spread awareness about clinical trials

There were numerous questions to be addressed. One question asked how patients view trials targeted at specific subsets of the T1D population compared to all open trials. My answer was that subsets are still part of the whole community, and a win in one group can expand to broader benefits. At the same time, being excluded from any study can feel deeply personal. People who have made the decision to participate and then hear they do not qualify may feel a sense of loss and frustration. That is where clear communication and education matter. Explaining why inclusion and exclusion criteria exist, offering information about other potential trials, and keeping lines of communication open helps people stay engaged rather than feeling shut out.

Alecia with two members of Breakthrough T1D’s Medical Affairs team, Julianne Lally (left) and Anastasia Albanese-O’Neill (right).

Recruitment, especially for new onset trials, is another challenge the panel addressed. Speed matters because opportunities for early intervention are time-sensitive. Effective recruitment requires a network approach. Endocrinologists and clinicians are critical, but so are community organizations, advocacy groups, and peer networks. Many newly diagnosed people search for help and connect with the T1D community to find resources. When trusted peers share information about trials, it not only demystifies the process and reduces the emotional burden for families facing a new diagnosis—it opens doors.

We also discussed patient-relevant endpoints in DMT trials. Clinical metrics matter, but they do not capture everything people live with. Participants prioritize outcomes that reduce daily burden, delay disease progression, improve long-term health, lower the risk of severe hypoglycemia, preserve endogenous insulin, enhance glycemic control, potentially reduce lifetime treatment costs, and sustain hope. These are the practical changes that matter in everyday life.

Education and implementation were the final themes I emphasized. Clinicians and patients alike need clear information about DMTs and about how early interventions would be implemented in real-world settings. Linking DMTs to screening efforts ensures that people in the early stages of T1D are identified and connected with options. Volunteers, advocacy groups, and community programs are essential for amplifying success stories and helping clinicians and patients understand how to access emerging therapies.

“Research is deeply personal”

All of this ties back to design. When we include lived experience in research design, the results are more humane, relevant, and practical. We reduce friction that prevents people from participating, and we improve outcomes by focusing on the needs of real users. My perspective as both a person who lives with T1D and an industrial designer helps me see where small design decisions have large effects.

Looking forward, I remain committed to this work because research is deeply personal. It saved my vision. It offers better tools and brighter possibilities. It is also a way to honor those who volunteered before me and to give others the chance to benefit. Whether I am advising on study protocols, speaking on national panels, or teaching people how to find trials, I see it as part of the same lifelong commitment: to make life with T1D easier, to improve the design of treatments and systems, and to help guide us toward the ultimate goal: cures.

What’s happening?

Today, Breakthrough T1D co-hosted an event with leading international diabetes organizations to discuss cardiovascular disease (CVD) and type 1 diabetes (T1D)—where we are, challenges that remain, and how we can work together in Europe and beyond to address this need for the T1D community.

The focus of the event: Doing more for CVD and T1D

This event, titled “Type 1 Diabetes & Cardiovascular Disease: From Data to Solutions,” took place today on November 14, 2025, in Brussels, Belgium. Breakthrough T1D co-hosted this event in conjunction with the International Diabetes Federation (IDF) Europe and the International Society for Pediatric and Adolescent Diabetes (ISPAD). The goal was to bring together different stakeholders to address a critical concern: the lack of therapies for cardiovascular disease for people living with T1D.

The speakers at the event covered a range of topics. Jonathan Rosen, Ph.D., Director of Research at Breakthrough T1D spoke about the often-overlooked link between CVD and T1D. Others touched upon lessons we can learn from  (T2D) diabetes and CVD, the gaps in evidence that still exist, new frontiers in CVD care for people living with autoimmune diseases, and the inclusion of T1D in CVD therapy development.

Attendees

From Breakthrough T1D:

Other attendees:

Why this matters

People living with T1D have a high risk of developing heart complications, despite advances in T1D care. At this time, there are only a few options available to lower this risk. In the United States and Europe, people with T1D have access to blood pressure medications and lipid-lowering medications (for example, statins) that can reduce the risk of developing CVD.

Other therapies, like the SLGT inhibitors empagliflozin or dapagliflozin, are the standard of care in the U.S. to treat heart failure in people without diabetes or with T2D. This class of drugs has revolutionized treatment and significantly reduced the rates of heart failure in these populations. However, people with T1D were excluded from these clinical trials—despite the fact that heart disease remains a critical concern for the T1D community. While not strictly approved, these drugs are occasionally prescribed off-label to reduce the risk of heart failure in people with T1D. Greater accessibility will require regulatory approval, and these options are not currently available for people living in Europe.

Despite the availability of some treatments that can reduce the risk of heart complications, there are no available cardioprotective therapies in the U.S. or Europe that can prevent CVD in people with T1D. More targeted, innovative therapies and treatment strategies are needed to further reduce the risk of—or ideally prevent altogether—cardiovascular complications in the T1D population.

There is a clear unmet need for the T1D community: the risk of CVD is high, and there are not enough options to treat or prevent it. That’s where events like these come in. They are a call to action for collaborative research efforts, better data integration, new and innovative ideas, and global cooperation towards a shared goal of better heart health for people living with T1D. The growing prioritization of CVD is evidenced by the European Commission’s cardiovascular health plan—which includes the Joint Action on Cardiovascular Diseases and Diabetes—showcasing how stakeholders in Europe are taking charge to accelerate breakthroughs for CVD and T1D.

What we’re saying

Addressing the challenge of cardiovascular complications is a cornerstone of our Improving Lives strategy. Breakthrough T1D is actively supporting clinical trials for therapies that can reduce or prevent CVD in people with T1D, and we are working on identifying new projects and researchers to fund to further accelerate these efforts.

We are committed—on a global scale—to making sure people with T1D live the best lives possible, which includes having accessible therapies that reduce the risk of heart complications. Events like these bring together the right people that can make this happen in Europe and beyond.

Bonjour from Montreal, Canada, where the latest and greatest in type 1 diabetes (T1D) research was presented at the International Society for Pediatric and Adolescent Diabetes (ISPAD) 51st Annual Conference. ISPAD is a yearly highlight of the T1D conference calendar, and this year was no exception. Scientists, clinicians, researchers, industry members, people with diabetes, and more were on hand to provide updates in cures, improving lives, access, and more—with much of it being supported by Breakthrough T1D.

Let’s take a look at the highlights.

About ISPAD

ISPAD is one of Breakthrough T1D’s peer organizations. They are dedicated to childhood and adolescent diabetes all over the world. In addition to collaborating in scientific advancements, Breakthrough T1D and ISPAD also fund several grants together—including providing support for clinical fellows from around the world to learn how to care for people with T1D from top-tier clinicians.

Tzield is being studied in kids under 8

Tzield has been in the news for a variety of reasons lately. Sanofi—the manufacturer of Tzield—recently received a voucher from the FDA for the use of Tzield in symptomatic, stage 3 T1D (for which it is not yet approved), potentially expediting the regulatory review process.

Tzield is currently approved for children and adults aged eight years and older in stage 2 T1D to delay the onset of stage 3 T1D. An ongoing study is investigating if Tzield can delay the progression of T1D from stage 2 to stage 3 in a new demographic: kids under eight.

At the ISPAD conference, researchers presented an interim analysis from the PETITE-T1D study, which is investigating if Tzield is as safe and tolerable in kids under eight in stage 2 T1D as it is in older individuals.

So far, 23 children have received a 14-day course of Tzield. To date, the safety and tolerability profile of Tzield is similar to that of older individuals who receive the drug. Two children in the study have progressed to stage 3 T1D.

This study is ongoing and we look forward to seeing more data.

Key takeaway

Tzield can delay T1D onset by an average of 3 years. This important study is determining if a new population—kids with T1D under eight years old—can benefit, and the data so far is encouraging.

Breakthrough T1D taking the stage

Breakthrough T1D leadership was on site to present and chair sessions.

Technology improves outcomes

A motif that was repeated by many, many investigators: automated insulin delivery (AID) systems help people do better. This spans several different technologies and systems: Tandem Control IQ, Minimed 780G, Cam APS, and OmniPod. Here’s why:

Key takeaway

It is widely established that AID systems lead to better outcomes. It’s important to continue to ensure that everyone has access to these systems and that they work better with less user input. They must become the standard of care across the world for kids with T1D.

The importance of clinical trials for stage 3 T1D

Stage 3 is when people are typically diagnosed with T1D. At this stage, beta cell function has not been completely eliminated. Individuals are still making insulin—not enough, but some. Decades of research by Breakthrough T1D and others has demonstrated clear benefits to holding onto beta cell function for as long as possible.

Clinical trials for individuals in stage 3 are few and far between. While there are exceptions (like the recently announced BARICADE-PRESERVE), we need more trials because people in stage 3 T1D can benefit from therapies to keep these cells alive and producing insulin for longer.

Key takeaway

Prioritizing clinical trials for stage 3 T1D—and recruiting for them—can be a bridge between better glycemic control today and future cures.

See you in 2026

2026 is going to be a big year—with many more T1D conferences to cover. This includes, for the first time, our very own conference: the 2026 Breakthrough T1D Clinical and Research Congress.

Stay tuned for the 2025 Top Advances piece in the coming weeks to see everything we’ve accomplished this year as we look towards the next one.  

To drive our mission forward, Breakthrough T1D financially supports type 1 diabetes (T1D) research through training awards and grants to academic scientists or clinicians, investments in promising companies, conference support, and more. Here, we take a deeper dive specifically into our training awards offered to early-stage researchers to understand the impact and outcomes that these awards have on individual careers and T1D research as a whole.

Why did we conduct this survey?

Training awards are a key part of Breakthrough T1D’s grants portfolio. These awards support early-career scientists and clinical researchers to explore promising ideas and encourage trainees to follow career paths that drive T1D research forward. Our approach is designed to provide opportunities to support trainees from an early postdoctoral stage (after receiving a higher degree) to transitioning to an independent lab and career as a T1D researcher.

Breakthrough T1D offers opportunities for funding at different stages of early career development on the path to independence.

Breakthrough T1D previously conducted surveys analyzing the impact and outcomes of training awards completed between 1974 to 2014, revealing that these awards encouraged long-term pursuit of a career in T1D. The current survey included an expanded analysis on training awards completed between 2015 to 2024. The results provide a broader understanding of how our financial support impacts research outcomes, career paths, and additional funding secured by awardees. This way, we can ensure that our funds for trainees are being used in the best way possible, supporting the best and brightest researchers and ideas that drive our mission forward now and in the future.

Survey methodology

From 2015 to 2024…

$62,513,719

Dollar amount of Breakthrough T1D funds invested in training awards

269

Number of training awards granted

230

Number of unique award recipients

Types of training awards surveyed

Training awardNumber of awards granted between 2015-2024Number of awards evaluated based on survey responses
Postdoctoral Fellowship15580
Advanced Postdoctoral Fellowship4835
Career Development Awards3626
Kellogg Family Early Career Patient-Oriented Diabetes Research Awards84
Transition Awards2217
Total269162

Of the total training awards funded between 2015 to 2024, this survey is a reflection of 135 respondents (60%) covering 162 awards. Respondent data was analyzed, mapped, and reported.

Impacts on career trajectories

17

Number of countries where respondents are located

76%

Percent of respondents who remained in academia after award completion

79%

Percent of respondents still working in diabetes (including T1D and type 2 diabetes) in both research and/or clinical practice


Number of respondents in the job they hold today (gray; “Today”) versus the job they took immediately after the training award ended (blue; “After award”).

Number and percent of respondents who reported whether Breakthrough T1D training awards influenced their decision to stay in diabetes research or clinical practice.

Areas of focus of respondents who stayed in diabetes research. Note that respondents could choose as many options as applicable.

Essential findings: Career trajectories for training award recipients

Impacts on research outcomes

Research supported by training awards resulted in a variety of outcomes that could benefit the larger scientific community and drive T1D research forward. Readouts of successful research include peer-reviewed journal publications, clinical trials, patents, collaborations, resources, grant review requests, and research honors or recognitions.

Number and percent of respondents who published research stemming from the training award in peer-reviewed journals.

463

Number of published papers reported by respondents

176

Number of journals that respondents published in


Number of clinical trials (17 total) initiated at different phases stemming from research completed with training award funds. These trials focused on new therapies, beta cell replacement, and improvements to closed-loop systems.

41

Number of patent-related activities reported from training awards

57%

Percent of respondents who formed at least one and often multiple collaborations throughout the training award

57

Number of different shareable resources developed by award recipients


Number of respondents (60%) who serve as grant reviewers at indicated agencies, broken out by training award mechanism. Invitations to review grants is a sign of scientific expertise in a given field.

39%

Percent of respondents who serve as grant reviewers for Breakthrough T1D

31

Percent of respondents who reported receiving at least one research honor


Percent and number of respondents who reported training their own diabetes research fellows.

91

Total number of research fellows trained by respondents

84%

Percent of next-generation trainees in academic research or clinical practice

Essential findings: Research outcomes stemming from awards

Impacts on securing additional funding

Breakthrough T1D training awards help early-career researchers continue an engaging and successful career in diabetes research. This is an important factor in securing further funding after the awards end, which helps researchers and clinicians maintain the ability to continue critical research that helps drive our mission forward.

78%

Percent of respondents who reported receiving additional research funding since the completion of the training award

$327,880,689

Dollar amount of additional research funding secured by respondents from various funding sources

Essential findings: Additional funds secured for research

Overall impacts on early career development

Top five areas of overall impact reported by respondents.

Essential findings: Impact on early career development as a whole

Training awards are key to achieving our mission

Based on these data, it’s clear that Breakthrough T1D’s training awards impact early-career researchers and clinicians across the board: from career development, to training the next generation, to securing additional research funding, to publishing more papers.

This is exemplified by feedback from trainees. Some reported that Breakthrough T1D’s training awards are the best in their class and are critical for T1D research, including the ability to execute niche projects that other funding agencies would not support. Most respondents reported being immensely grateful for their training awards. See what some of the awardees have to say:


Ways in which respondents (50%) continued to engage with Breakthrough T1D after the award ended, parsed out by training award mechanism.

Not only do these awards help retain talent in diabetes research, but they also help awardees maintain connections with Breakthrough T1D as a whole—outside of seeking financial support. Training award recipients have presented research updates at local events, participated in Breakthrough T1D fundraising activities, and supported our advocacy efforts. We are helping to build the next generation of T1D researchers, advocates, T1D community supporters, and more—all working toward the same goal of a world without T1D.

This survey has put into context where our money is going—and it’s going to the right places. Helping to train the next generation of scientists and clinicians is key to the success of our mission. We’re seeing significant returns on our investments, embodied by trainees securing substantial funding for ongoing T1D research, the creation of shareable resources that will help drive research forward and increase collaboration, and the success of our awardees in securing desirable jobs and leadership positions.

We put our time and money into identifying the best-and-brightest scientists and ideas, encourage them to stay in the field, and guide them as they pass the torch to the upcoming talented pool of young T1D researchers. We support scientists so they can do the important work that will help people with T1D live better lives—and maybe one day live without T1D. And, most importantly, we wouldn’t be able to do this without YOU: our supporters, our donors, and the entire T1D community that allows us to do what we do every day—improve the lives of people with T1D as we drive towards a cure. Thank you.

The full-length report was put together with the assistance of Breakthrough T1D consultant Kim Hunter-Schaedle.

Since 1994, Marshalls has been a committed supporter of Breakthrough T1D.

As Breakthrough T1D’s largest corporate partner, Marshalls raises more than $3 million each year through in-store fundraisers at checkout, donations from the TJX Foundation, and store support of local Breakthrough T1D chapters across the country. These combined efforts have resulted in more than $47 million in donations to-date for Breakthrough T1D, helping to advance our mission of accelerating life-changing breakthroughs to cure, prevent, and treat type 1 diabetes (T1D) and its complications.

Marshalls’ 2025 in-store fundraising campaign for Breakthrough T1D runs from Sunday, August 31, through Saturday, September 27. Find your local Marshalls here.

Creating a better future

Digital creator Kris Leepper

Digital creator Kris Leeper’s type 1 diabetes journey began with his diagnosis in 2013. It was, in his own words, “terrifying.”

“My wife and I were bombarded with conflicting information,” Kris said. “We were navigating unchartered territory as a family, just two years into our marriage. I felt lost and uncertain about the future.”

T1D technology changed the game for Kris. “The introduction of a continuous glucose monitor (CGM) and pump revolutionized my outlook on living with T1D. I immediately felt better,” he said. “Access to and understanding of diabetes technology has profoundly improved my daily life.”

Kris appreciates Marshalls for bringing awareness to Breakthrough T1D’s efforts to make life-changing technologies a reality for the more than 1.5 million Americans facing T1D.

“Companies like Marshalls play a pivotal role in bringing Breakthrough T1D’s mission to the mainstream,” he said. “Marshalls’ support for advocacy, research, and fundraising demonstrates the power of a major brand in creating a better future for people living with or caring for those with T1D.”

Driving breakthroughs forward

1 in every 31 families in the U.S. are impacted by type 1 diabetes—it places a tremendous financial, emotional, and mental burden on those who live with it and their loved ones. With support from partners like Marshalls, Breakthrough T1D is making everyday life with T1D safer and easier through technology—like the CGM Kris uses, and automated insulin delivery systems.

Every donation collected through the Marshalls partnership has also helped drive critical research in cures for type 1 diabetes. From the launch of the Special Diabetes Program in 1997, to the first manufactured islets making insulin in 2014, and the FDA approval of Tzield, the first disease-modifying therapy for type 1 diabetes, Breakthrough T1D is driving innovation forward to make the condition a thing of the past.

“The future of type 1 diabetes is bright,” Kris said. “We are on the cusp of living longer, experiencing fewer complications, and enjoying a life without limits.”

Breakthrough T1D thanks Marshalls for its incredible partnership in improving and changing life with type 1 diabetes.

Hy-Vee’s dedication to Breakthrough T1D’s mission is personal.

Type 1 diabetes (T1D) first struck the Hy-Vee family in 1921, when company co-founder Charles Hyde’s oldest son, Paul, died from the disease when he was 8 years old.

Since 1998, Hy-Vee has been a trusted partner of Breakthrough T1D, raising nearly $20 million through a variety of corporate and store events, including Walks in the Midwestern and Southern U.S. Hy-Vee also participates in Rides across the country; in 2025, they were recognized as a top fundraising team, bringing in over $230,000 for T1D research.

Hy-Vee’s 2025 in-store fundraising campaign for Breakthrough T1D runs from September 1 through 30. Find your local Hy-Vee here.

Working together for cures

Breakthrough T1D fundraisers and advocates the Raiche family

Sam and Lauren Raiche are loyal Hy-Vee customers. They’re also dedicated fundraisers, advocates, and volunteers for Breakthrough T1D. Their 8-year-old son, Alexander, was diagnosed with T1D at age 3.

They appreciate Hy-Vee’s commitment to Breakthrough T1D’s mission. “It means so much to know that a company we already trust and shop with is also supporting a mission so close to our hearts,” Lauren said. “Living with type 1 diabetes is a daily challenge for our family, and seeing Hy-Vee stand behind research and programs that directly impact families like ours makes us feel grateful and supported every time we walk through their doors.”

Alexander represented Kansas at the 2025 Breakthrough T1D Children’s Congress. As a Delegate, he met with representatives to advocate for renewal of the Special Diabetes Program, which funds critical type 1 diabetes research. “Advocacy has become a cornerstone of our journey,” Lauren said. “We firmly believe that raising awareness and engaging with the community are essential steps toward making meaningful progress and, ultimately, achieving cures.”

Accelerating cell therapy breakthroughs

Support from partners like Hy-Vee helps fuel that progress toward cures for type 1 diabetes. Breakthrough T1D’s cures portfolio includes cell therapies, which replace destroyed beta cells with protected functional cells to restore insulin therapy independence and glucose control, ideally without immunosuppression.

Over the past decade, Breakthrough T1D has funded more than $156 million in cell therapies research, including partnerships with organizations like Vertex Pharmaceuticals and Sana Biotechnology.

In 2024, Vertex launched a pivotal clinical trial for zimislecel (formerly VX-880), which uses manufactured islets to restore the body’s ability to produce insulin. The therapy, however, requires the use of immunosuppression to protect the transplanted cells from rejection. The islets used in zimislecel are derived from the Breakthrough T1D-funded work of Doug Melton, Ph.D., who first turned precursor cells into insulin-producing cells in 2014.

A 2025 study from Sana Biotechnology showed that hypoimmune (HIP) donor-derived islets are making insulin and avoiding immune detection in the first person treated. The T1D Fund: A Breakthrough T1D Venture invested in Sana to help advance their HIP technology platform.

Breakthrough T1D continues to drive innovation to develop cell replacement therapies and eliminate the need for immunosuppression. With the generosity and support of partners like Hy-Vee and families like the Raiches, we will change the lives of everyone facing type 1 diabetes.

Breakthrough T1D is Wawa’s longest-standing partnership. Since 1994, the popular convenience store chain has raised millions of dollars for type 1 diabetes (T1D) research through in-store fundraising campaigns at more than 1,060 locations across the Eastern U.S.

Wawa’s partnership with Breakthrough T1D is further enhanced by donations from The Wawa Foundation, which is committed to helping Breakthrough T1D create a world without T1D and building strong communities by supporting causes related to health, hunger, and everyday heroes. 

Wawa’s 2025 fundraising campaign for Breakthrough T1D runs from July 31 to August 20. Customers can donate $1, $3, or $5 or round up at checkout to support life-changing breakthroughs for people living with T1D.

Wawa lives out the values it speaks to

Wawa super fan, Nate Keeney, has lived with T1D for 27 years. He is proud to support a company that lives out the values it speaks to.

“Long before working at Breakthrough T1D, I loved Wawa for their larger selection of food options and snacks,” Nate said. “I always knew they partnered with the organization, but seeing how their efforts impact everyone living with T1D has given me a renewed passion to continue supporting Wawa.”

Wawa walks to cure T1D

Breakthrough T1D Walk is another way Wawa helps support the T1D community and fund critical T1D research. The Wawa Foundation matches employee Walk fundraising efforts up to $100.

Wawa associates also volunteer at Walk events to distribute in-kind food and beverages to participants.

“I see Wawa everywhere at our local Breakthrough T1D Walk in Philadelphia, with their classic soft pretzels and iced teas (and diet iced teas!) to fuel us as we walk to support T1D research and community,” Nate said. “The Goose also leads the T1D parade before the Walk begins.”

Wawa helps fuel life-changing research

Wawa helps Breakthrough T1D advance its mission to accelerate life-changing breakthroughs to cure, prevent, and treat type 1 diabetes and its complications.

That includes technology like continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems, which have been life-changing for Nate.

“My insulin pump and CGM have been a wonderful addition to my diabetes routine—they’ve helped me get my A1c into a great range and identify trends,” he said. “Also, the ability to manage my T1D from my phone has made life on the go easier, whether it’s traveling for work or traveling for fun to different states or countries.”

Wawa’s support also fuels research in cures for type 1 diabetes. Cell therapies that insert healthy insulin-producing cells into people with T1D with minimal or no immunosuppression is a breakthrough Nate is hopeful for.

“So much effort, intensity, and care are going into funding research, particularly with cell therapies,” he said. “It makes me hopeful for cures within my lifetime.”

Together, Wawa and Breakthrough T1D are championing life-changing research and strengthening the T1D community.

The short version

Breakthrough T1D’s newest publication outlines what the future of beta cell replacement therapies looks like—and how we can make these therapies a reality for everyone with type 1 diabetes (T1D) who wants them through innovative clinical trial design and expanding the pool of eligible trial participants.

Breakthrough T1D, in collaboration with other leading experts in the field, recently published an article titled “Future Directions and Clinical Trial Considerations for Novel Islet β-Cell Replacement Therapies for Type 1 Diabetes” in the journal Diabetes. Breakthrough T1D Research and Advocacy staff who contributed to the publication include Sanjoy Dutta, Ph.D., Chief Scientific Officer, Esther Latres, Ph.D., Vice President of Research, and Marjana Marinac, Pharm.D., Associate Vice President of Regulatory Affairs.

Beta cell replacement therapies have the potential to cure type 1 diabetes (T1D) by removing the need for external insulin. While donor islet transplantation can result in insulin independence and results from early trials with manufactured islets are encouraging, people with T1D need better tools and therapies. This publication serves as a roadmap for the entire field—including researchers, product developers, industry, regulators, clinicians, and people with T1D—to address these needs and ensure that beta cell replacement therapies can get to people with T1D as quickly and safely as possible.

Read on to learn more about what the future of beta cell replacement therapies looks like.

Where we are now

People living with T1D depend on external insulin to manage their condition throughout their lives. Despite advancements in diabetes technology, such as continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems, most people with T1D are unable to achieve blood sugar targets, rendering them at a higher risk for complications, reduced quality of life, and lower life expectancy.

 It’s simple: we need to do more for the T1D community.

One promising avenue to meet these needs is through cell replacement therapy. Lantidra®, the first FDA-approved donor-derived islet replacement therapy for T1D, has proven to be safe and effective in eliminating severe hypoglycemia, providing insulin independence, and improving quality of life. However, this therapy is limited to people with severe hypoglycemia and requires immunosuppression to prevent rejection of the transplanted cells, which can have side effects. Even more, these donor-derived islets are in limited supply.

Alternative beta cell replacement therapies are emerging—and we can no longer limit their development to people experiencing severe hypoglycemia.

As stated in the publication:

Given the proven benefits of islet transplantation extending far beyond the amelioration of severe hypoglycemia that has been documented and the understanding of the risk profile gained over the past 20 years, consideration must be given to broadening the application for islet beta cell replacement.

Developing cell therapy strategies to meet unmet needs of the T1D population

Breakthrough T1D’s vision for the T1D community includes beta cell replacement therapies with no immunosuppression that are available to everyone who wants them. We are committed to making this a reality through our Project ACT (Accelerate Cell Therapies) initiative, which will accelerate the development of these therapies to achieve our vision as quickly as possible.

We are entering an exciting era of beta cell replacement. Emerging therapies are addressing challenges such as cell source and scalability, resulting in the development of islets derived from sources other than donors, including manufactured islets and porcine islets. Up-and-coming therapies are also testing different transplantation sites, methods of delivery, and cell protection strategies to prevent immune rejection with the fewest side effects possible (and ideally no immunosuppression). Learn more about what scientists are doing to optimize beta cell replacement therapies.

Breakthrough T1D’s continuous support of many of these therapies, such as Vertex’s manufactured islet therapy zimislecel, has been critical to accelerating them through the clinical pipeline. Explore emerging beta cell replacement therapies in clinical trials now—and see how Breakthrough T1D’s commitment to these therapies helped make this possible.

When successful, the advent of new, safe, scalable, and effective beta cell replacement therapies will provide the T1D community with options. As these therapies are moving their way through the pipeline, we need to ensure they are being studied in a broader T1D population who stand to benefit.

So, how do we make this happen?

Breakthrough T1D’s roadmap for the future development of beta cell replacement therapies in T1D.

The roadmap for emerging beta cell replacement therapies

The goal

Accelerate availability of emerging next-generation beta cell replacement therapies for every person with T1D who wants them by designing clinical trials that speed their development, regulatory approval, access, and adoption.

Expanding the T1D population eligible for beta cell transplantation

Current trials testing beta cell therapies necessitating immunosuppression require participants to have elevated HbA1c levels and recurrent severe hypoglycemic events. This limits the pool of participants to people who meet the requirements and are most likely to benefit, given the side effects associated with chronic, broad immunosuppressants.

Clinical trials for emerging beta cell replacement therapies should broaden eligibility criteria so more people with T1D can participate—and experience the potential benefits. When designing new clinical trials, sponsors and regulators should consider including a broader range of HbA1c levels, clinically important or serious hypoglycemic events, and other complications.

Studies have found that the T1D community is generally open to beta cell replacement therapies as a potential solution to T1D, and people are willing to accept the associated risk versus benefit considerations for the possibility of becoming insulin independent. A Breakthrough T1D assessment also found that physicians are interested in recommending beta cell replacement therapies to people with T1D—especially if they don’t require immunosuppression.

Placing people with T1D at the center of clinical trial design

The outcomes used to assess the effectiveness of cell therapies currently in clinical trials, including those involving deceased donor islets, are acceptable for emerging beta cell replacement therapies. These include on-target HbA1c levels, absence of severe hypoglycemia, significant reduction or elimination of external insulin, and restoration of the body’s insulin production as measured by C-peptide.

Other endpoints that should be considered include CGM metric targets like time-in-range in addition to person-reported outcomes. Understanding how a beta cell therapy may affect a person’s health-related quality of life—such as diabetes distress, fear of hypoglycemia, or social and family dynamics—will be critically important for calculating the risk to benefit ratio of these therapies.

Read more about why person-reported outcomes are important for cell therapies.

“There are still significant unmet needs in the T1D community. Breakthrough T1D’s roadmap is supported by the assessment of clinically meaningful outcomes and driving research toward solutions that address key factors such as cell sources and protections strategies that will broaden the people with T1D who could benefit from emerging cell replacement therapies.”

Esther Latres, Ph.D., Vice President of Research

Innovative trial designs to accelerate development of cell therapies

Clinical trials for beta cell replacement therapies are generally based on a single-arm, open-label design—meaning there is no placebo group and both participants and researchers know which therapy is being administered. While this design can work for emerging beta cell therapies, single trials with multiple arms testing alternative transplant sites, immune protection strategies, or other methods have the potential to speed up the pace of development.

Similarly, adaptive trial designs use mid-trial interim analyses of study data to inform the remainder of the trial. This helps researchers learn what’s working (or not working) and adjust the design accordingly, with guidance from regulatory agencies, so the rest of the trial is a focused and efficient use of time and resources. Potential interim changes to trial design include reducing the number of participants required, eliminating doses, recruiting people who are most likely to benefit, or stopping the trial outright due to clear success or failure.

By applying guidance in therapeutic development and innovative trial designs to emerging beta cell replacement therapies, we can move early-stage trials along faster, thereby allowing regulators to make decisions sooner. To support quicker trials and reduce the possibility for delays, researchers, developers, and regulators around the world need to work together to achieve convergence on trial populations, endpoints, and innovative designs that will meet regional requirements.

Learning from past successes

People with T1D continue to live with unmet needs with still significant risk for long-term complications, and they need more therapeutic options. Right now, most clinical trials for beta cell replacement therapies requiring immunosuppression are limited to a small portion of the T1D population. This needs to change—especially given the potential for insulin independence. The T1D community must be put first when making decisions about beta cell replacement therapies, and Breakthrough T1D is making sure that this happens.

Adjusting how we approach clinical trials for emerging beta cell replacement therapies will be critical for ensuring we accelerate the research, development, regulatory approval, access and adoption of these novel therapies. Breakthrough T1D successfully accomplished this for AID systems—and we are confident that following a similar roadmap for cell therapies will get us to the finish line, faster.

The journey of AID systems

Learn more about the critical role of Breakthrough T1D in driving AID systems forward, recounted by Breakthrough T1D volunteer Doug Lowenstein.

Curative therapies for T1D are in reach. This roadmap, in conjunction with our Project ACT initiative, is key to bringing beta cell replacement therapies to every person with T1D who wants them.

To make this a reality, everyone needs to work together. As stated in the publication, “This requires a comprehensive strategy and a coordinated collaboration across stakeholders in every field relevant to islet cell replacement.” This roadmap is a guide for moving toward our common goal of a cure for T1D as soon as possible.

Breakthrough T1D will continue to lead the way until the T1D community can choose the beta cell replacement therapy that works best for them, regardless of blood glucose management or hypoglycemia status. Everyone deserves the chance to benefit.

Breakthrough T1D, in partnership with Friends of Mewar and UNICEF, participated in the Udaipur Type 1 Diabetes Summit: Advancing Access, Equity, and Action, in Udaipur, Rajasthan, India. The event gathered government leaders, health experts, community advocates, and international partners to develop a collaborative roadmap for strengthening type 1 diabetes (T1D) care across India.

Breaking down barriers and stigma

Hosted by Friends of Mewar’s Founder and Breakthrough T1D Global Ambassador Princess Padmaja Kumari Parmar, who has lived with T1D for more than 40 years, the two-day summit was a critical milestone in building partnerships that drive sustainable, system-wide improvements in T1D care and equity.

“Timely healthcare access and accurate information are vital for managing type 1 diabetes and other non-communicable diseases,” said Princess Padmaja. “Collaboration is key to breaking down barriers and stigma, and ensuring that children and youth receive the support they deserve.”

Topics discussed included integrating T1D into national health frameworks, scaling digital and rural care solutions, promoting equity and stigma reduction, and aligning regional action across Southeast Asia. The summit also featured updates on the T1D Basic Care Pilot Program, a partnership between Breakthrough T1D and the William J. Clinton Foundation, showcasing early successes in improving insulin and glucose monitoring availability in public health settings.

The Udaipur Type 1 Diabetes Summit concluded Princess Padmaja’s strong call for sustained innovation, investment, and partnership to address the urgent need for support for youth living with T1D in India and around the world.

Advancing cures while improving lives

The summit aligned with Breakthrough T1D’s mission of advancing cures while improving lives. Affordable insulin, access to T1D technology, early diagnosis to prevent complications at diagnosis, and psychosocial support are all critical to improved health outcomes on the path to cures.

“In India and many other countries, children and young people face significant barriers to care,” said Lynn Starr, Chief Global Advocacy Officer at Breakthrough T1D. “Our commitment is that when cures arrive, they are accessible to everyone, everywhere, regardless of geography or income.”

Driving change for the T1D community

Princess Padmaja Kumari Parmar, Global Ambassador and host. of the Udaipur Type 1 Diabetes Summit

Born in Udaipur, Rajasthan, India, Princess Padmaja was diagnosed with T1D at age 5. At the time of her diagnosis, tools and insulin options for managing T1D were limited—checking blood glucose levels or dosing insulin based on carbohydrate quantities wasn’t even possible.  

“Witnessing the progression of T1D breakthroughs over the years has been nothing short of remarkable,” said Princess Padmaja. “When I first started insulin injections, it was a cumbersome routine, requiring multiple injections a day. Today, thanks to advancements in insulin pump technology, managing T1D has become more streamlined and efficient, improving my quality of life.” 

As a Breakthrough T1D Global Ambassador, Princess Padmaja is working to combat the stigma of T1D and address the challenges surrounding the condition. She hopes to inspire changes within the government’s policies that could support people with T1D and within India’s healthcare system. 

“As a Global Ambassador, my aspirations do extend beyond borders,” she said. “The challenges surrounding T1D are not exclusive to India; they are present globally.” 

“By rallying support and implementing these measures, I can help tackle these challenges, ultimately improving the quality of life for those with T1D.”